We are developing a platform technology for preventing or treating a wide spectrum of medical conditions where the current standard of care is not optimal. Our proprietary oromucosal patch is embedded with a biologic (immunoglobulin or “IgG”) that is known from extensive clinical work to calm an overactive immune system. If shown to be effective in our clinical trial, the patch could be used to reduce or eliminate cytokine storms associated with a wide range of infectious and non-infectious diseases such as pneumonia, sepsis and cancer.  Our goal is to avoid systemic immune suppression seen with intravenously administered IgG (IVIG) by leveraging the oral immune system to deliver the biologic using a more targeted approach. The oral patch is non-invasive, fully biodegradable, and provides up to 1000x less IgG allowing more patients to be served with a lower overall dose.